## Michele M Gorczyca

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4740079/publications.pdf

Version: 2024-02-01

7 papers	432 citations	1478505 6 h-index	7 g-index
7	7	7	669
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3KÎ <sup>2</sup> Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2021, 27, 5248-5257.	7.0	15
2	Targeting B-cell maturation antigen with GSK2857916 antibody–drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial. Lancet Oncology, The, 2018, 19, 1641-1653.	10.7	193
3	Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy. Leukemia and Lymphoma, 2017, 58, 348-356.	1.3	3
4	Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leukemia and Lymphoma, 2017, 58, 1084-1093.	1.3	48
5	Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia and Lymphoma, 2016, 57, 2037-2046.	1.3	20
6	Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood, 2011, 117, 6450-6458.	1.4	121
7	Inhibition of human cytomegalovirus protease by enedione derivatives of thieno[2,3-d]oxazinones through a novel dual acylation/alkylation mechanism. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 449-452.	2.2	32